Harnessing HLA-E-restricted CD8 T lymphocytes for adoptive cell therapy of patients with severe COVID-19.
作者信息
Caccamo Nadia, Sullivan Lucy C, Brooks Andrew G, Dieli Francesco
机构信息
Central Laboratory for Advanced Diagnosis and Biomedical Research, University of Palermo, Palermo, Italy.
Department of Biomedicine, Neuroscience and Advanced Diagnosis, University of Palermo, Palermo, Italy.
出版信息
Br J Haematol. 2020 Aug;190(4):e185-e187. doi: 10.1111/bjh.16895. Epub 2020 Jun 19.
Abstract
摘要
相似文献
1
Harnessing HLA-E-restricted CD8 T lymphocytes for adoptive cell therapy of patients with severe COVID-19.利用HLA-E限制性CD8 T淋巴细胞对重症COVID-19患者进行过继性细胞治疗。
Br J Haematol. 2020 Aug;190(4):e185-e187. doi: 10.1111/bjh.16895. Epub 2020 Jun 19.
2
Off-the-Shelf Partial HLA Matching SARS-CoV-2 Antigen Specific T Cell Therapy: A New Possibility for COVID-19 Treatment.现成的部分 HLA 匹配 SARS-CoV-2 抗原特异性 T 细胞疗法：COVID-19 治疗的新可能性。
Front Immunol. 2021 Dec 23;12:751869. doi: 10.3389/fimmu.2021.751869. eCollection 2021.
3
Repurposing CD8 T cell immunity against SARS-CoV-2 for cancer immunotherapy: a positive aspect of the COVID-19 pandemic?重新利用针对 SARS-CoV-2 的 CD8 T 细胞免疫应答进行癌症免疫治疗：COVID-19 大流行的一个积极方面？
Oncoimmunology. 2020 Jul 16;9(1):1794424. doi: 10.1080/2162402X.2020.1794424.
4
Immunogenic T cell epitopes of SARS-CoV-2 are recognized by circulating memory and naïve CD8 T cells of unexposed individuals.SARS-CoV-2 的免疫原性 T 细胞表位可被未暴露个体的循环记忆和幼稚 CD8 T 细胞识别。
EBioMedicine. 2021 Oct;72:103610. doi: 10.1016/j.ebiom.2021.103610. Epub 2021 Oct 6.
5
Rapid GMP-Compliant Expansion of SARS-CoV-2-Specific T Cells From Convalescent Donors for Use as an Allogeneic Cell Therapy for COVID-19.从恢复期供体中快速符合 GMP 要求的扩增 SARS-CoV-2 特异性 T 细胞，用作 COVID-19 的同种异体细胞治疗。
Front Immunol. 2021 Jan 8;11:598402. doi: 10.3389/fimmu.2020.598402. eCollection 2020.
6
CD8 T-Cell Epitope Variations Suggest a Potential Antigen HLA-A2 Binding Deficiency for Spike Protein of SARS-CoV-2.CD8 T 细胞表位变异提示 SARS-CoV-2 刺突蛋白潜在的抗原 HLA-A2 结合缺陷。
Front Immunol. 2022 Jan 18;12:764949. doi: 10.3389/fimmu.2021.764949. eCollection 2021.
7
HLA-A02:01 restricted T cell receptors against the highly conserved SARS-CoV-2 polymerase cross-react with human coronaviruses.针对高度保守的 SARS-CoV-2 聚合酶的 HLA-A02:01 限制性 T 细胞受体与人冠状病毒发生交叉反应。
Cell Rep. 2021 Dec 28;37(13):110167. doi: 10.1016/j.celrep.2021.110167. Epub 2021 Dec 10.
8
SARS-CoV-2-specific CD8 T-cell responses and TCR signatures in the context of a prominent HLA-A*24:02 allomorph.在主要 HLA-A*24:02 同种异型的背景下，SARS-CoV-2 特异性 CD8 T 细胞反应和 TCR 特征。
Immunol Cell Biol. 2021 Oct;99(9):990-1000. doi: 10.1111/imcb.12482. Epub 2021 Jun 30.
9
Dynamic SARS-CoV-2-Specific Immunity in Critically Ill Patients With Hypertension.急危重症高血压患者的 SARS-CoV-2 特异性动态免疫。
Front Immunol. 2020 Dec 10;11:596684. doi: 10.3389/fimmu.2020.596684. eCollection 2020.
10
Optimization of antigen-specific CD8 T cell activation conditions for infectious diseases including COVID-19.优化针对传染病（包括 COVID-19）的抗原特异性 CD8 T 细胞激活条件。
STAR Protoc. 2021 Sep 17;2(3):100789. doi: 10.1016/j.xpro.2021.100789. Epub 2021 Aug 14.
引用本文的文献
1
A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19.关于COVID-19的药物制剂、免疫疗法和支持性疗法的全面综述。
Narra J. 2022 Dec;2(3):e92. doi: 10.52225/narra.v2i3.92. Epub 2022 Dec 8.
2
3
The promiscuous development of an unconventional Qa1b-restricted T cell population.非常规 Qa1b 限制性 T 细胞群体的混杂发育。
Front Immunol. 2023 Oct 31;14:1250316. doi: 10.3389/fimmu.2023.1250316. eCollection 2023.
4
Immune-Cell-Based Therapy for COVID-19: Current Status.基于免疫细胞的 COVID-19 治疗：现状。
Viruses. 2023 Oct 25;15(11):2148. doi: 10.3390/v15112148.
5
Adoptive T-cell therapies to overcome T cell-dependent immune dysregulations in COVID-19.采用过继性T细胞疗法克服COVID-19中T细胞依赖性免疫失调。
Turk J Biol. 2021 Dec 20;46(2):105-117. doi: 10.3906/biy-2109-85. eCollection 2022.
6
HLA-E*01:01 + HLA-E*01:01 genotype confers less susceptibility to COVID-19, while HLA-E*01:03 + HLA-E*01:03 genotype is associated with more severe disease.HLA-E*01:01+ HLA-E*01:01 基因型可降低感染 COVID-19 的易感性，而 HLA-E*01:03+ HLA-E*01:03 基因型与更严重的疾病相关。
Hum Immunol. 2023 Apr;84(4):263-271. doi: 10.1016/j.humimm.2023.02.002. Epub 2023 Feb 13.
7
A systemic review of T-cell epitopes defined from the proteome of SARS-CoV-2.SARS-CoV-2 蛋白质组中定义的 T 细胞表位的系统评价。
Virus Res. 2023 Jan 15;324:199024. doi: 10.1016/j.virusres.2022.199024. Epub 2022 Dec 13.
8
Narrative review of the relationship between the maternal-fetal interface immune tolerance and the onset of preeclampsia.母胎界面免疫耐受与子痫前期发病关系的叙述性综述。
Ann Transl Med. 2022 Jun;10(12):713. doi: 10.21037/atm-22-2287.
9
A review of mass spectrometry-based analyses to understand COVID-19 convalescent plasma mechanisms of action.基于质谱分析的 COVID-19 恢复期血浆作用机制研究综述。
Proteomics. 2022 Sep;22(18):e2200118. doi: 10.1002/pmic.202200118. Epub 2022 Jul 15.
10
Elucidating T Cell and B Cell Responses to SARS-CoV-2 in Humans: Gaining Insights into Protective Immunity and Immunopathology.阐明人类对 SARS-CoV-2 的 T 细胞和 B 细胞反应：深入了解保护性免疫和免疫病理学。
Cells. 2021 Dec 27;11(1):67. doi: 10.3390/cells11010067.
本文引用的文献
1
Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals.COVID-19 疾病患者和未接触者体内针对 SARS-CoV-2 冠状病毒的 T 细胞反应的靶标。
Cell. 2020 Jun 25;181(7):1489-1501.e15. doi: 10.1016/j.cell.2020.05.015. Epub 2020 May 20.
2
Convalescent donor SARS-COV-2-specific cytotoxic T lymphocyte infusion as a possible treatment option for COVID-19 patients with severe disease has not received enough attention till date.恢复期供体的新冠病毒特异性细胞毒性T淋巴细胞输注作为重症COVID-19患者的一种可能治疗选择，迄今为止尚未得到足够关注。
Br J Haematol. 2020 Jun;189(6):1062-1063. doi: 10.1111/bjh.16780. Epub 2020 May 19.
3
The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease.细胞因子（包括白细胞介素 6）在 COVID-19 诱导性肺炎和巨噬细胞活化综合征样疾病中的作用。
Autoimmun Rev. 2020 Jun;19(6):102537. doi: 10.1016/j.autrev.2020.102537. Epub 2020 Apr 3.
4
Functional exhaustion of antiviral lymphocytes in COVID-19 patients.新冠病毒肺炎患者抗病毒淋巴细胞的功能耗竭
Cell Mol Immunol. 2020 May;17(5):533-535. doi: 10.1038/s41423-020-0402-2. Epub 2020 Mar 19.
5
The convalescent sera option for containing COVID-19.使用康复期血清来控制新型冠状病毒肺炎。
J Clin Invest. 2020 Apr 1;130(4):1545-1548. doi: 10.1172/JCI138003.
6
HLA-E-restricted CD8 T Lymphocytes Efficiently Control and HIV-1 Coinfection.HLA-E 限制性 CD8 T 淋巴细胞能够有效控制 HIV-1 合并感染。
Am J Respir Cell Mol Biol. 2020 Apr;62(4):430-439. doi: 10.1165/rcmb.2019-0261OC.
7
Pathogen-derived HLA-E bound epitopes reveal broad primary anchor pocket tolerability and conformationally malleable peptide binding.病原体衍生的 HLA-E 结合表位揭示了广泛的主要锚定口袋耐受性和构象可变形的肽结合。
Nat Commun. 2018 Aug 7;9(1):3137. doi: 10.1038/s41467-018-05459-z.
8
Detailed characterization of human Mycobacterium tuberculosis specific HLA-E restricted CD8 T cells.详细描述人类结核分枝杆菌特异性 HLA-E 限制性 CD8 T 细胞。
Eur J Immunol. 2018 Feb;48(2):293-305. doi: 10.1002/eji.201747184. Epub 2017 Dec 15.
9
MHC Ib molecule Qa-1 presents Mycobacterium tuberculosis peptide antigens to CD8+ T cells and contributes to protection against infection.MHC Ib分子Qa-1将结核分枝杆菌肽抗原呈递给CD8+ T细胞，并有助于抵御感染。
PLoS Pathog. 2017 May 5;13(5):e1006384. doi: 10.1371/journal.ppat.1006384. eCollection 2017 May.
10
Broadly targeted CD8⁺ T cell responses restricted by major histocompatibility complex E.由主要组织相容性复合体E限制的广泛靶向性CD8⁺T细胞反应
Science. 2016 Feb 12;351(6274):714-20. doi: 10.1126/science.aac9475. Epub 2016 Jan 21.
Zotero 插件